Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Negative Driver Genes and Failed Immunotherapy

NCT06467500 is registered in ClinicalTrials.gov with Xin-Hua Xu as lead sponsor.

NCT NCT06467500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06467500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Negative Driver Genes and Failed Immunotherapy
Lead sponsor
Xin-Hua Xu
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2024
Completion date
December 30, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer